New England Journal of Medicine · 1982 · 990 citations · 15 references
MedicineCancer BiologyOncologyCancer ImmunologyMonoclonal AntibodiesTumor ImmunologyAntibody CharacterizationB Cell BiologyDiagnostic Monoclonal AntibodiesLymphoid NeoplasmsLymphoid TumorsTumor AntigensAntibodiesLymphoma ImmunophenotypingMonoclonal Antibodies In CancerMonoclonal Antibodies In Oncology
Human B‑cell lymphomas arise from clonal proliferation of cells expressing a unique monoclonal surface immunoglobulin, whose variable region (idiotype) serves as a tumor‑specific marker distinguishing malignant from normal B cells. Anti‑idiotype antibodies have been shown to monitor B‑cell tumors and to investigate their biology. No additional information is provided.
HUMAN B-cell malignant tumors result from the proliferation of single clones of cells that express surface markers characteristic of normal B lymphocytes.1 , 2 In particular, the surface immunoglobulin expressed by these cells is monoclonal — i.e., restricted to a single light-chain type and to a particular variable region unique to each case. The unique immunoglobulin variable region (idiotype) of each lymphoma clone may be considered a tumor-specific marker, distinguishing tumor cells from normal cells in the patient. We and others have shown that anti-idiotype antibodies can be used to monitor B-cell tumors and to investigate the biology of these tumors.3 4 5 Because . . .
15
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody
J Ritz, JM Pesando, SE Sallan et al. · Blood · 1981 · 321 citations · Full text
Medicine, Hematology, Oncology +14
The monoclonality of human B-cell lymphomas.
Ronald Levy, R Warnke, R. F. Dorfman et al. · The Journal of Experimental Medicine · 1977 · 268 citations · Full text
Medicine, Immunology, Pathology +17